Magnus Maria Christine, Örtqvist Anne Kristina, Urhoj Stine Kjaer, Aabakke Anna, Mortensen Laust Hvas, Gjessing Håkon, Nybo Andersen Anne-Marie, Stephansson Olof, Håberg Siri Eldevik
Centre for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway.
Department of Medicine, Karolinska Institute, Stockholm, Sweden.
BMJ Public Health. 2023 Oct 25;1(1):e000314. doi: 10.1136/bmjph-2023-000314. eCollection 2023 Nov.
A few studies indicate that women infected with SARS-CoV-2 during pregnancy might have an increased risk of stillbirth. Our aim was to investigate the risk of stillbirth according to infection with SARS-CoV-2 during pregnancy also taking the variant into account.
We conducted a register-based study using the Swedish, Danish and Norwegian birth registries. A total of 389 949 births (1013 stillbirths) after 22 completed gestational weeks between 1 May 2020 and end of follow-up (27 January 2022 for Sweden and Norway; 31 December 2021 for Denmark). We estimated the risk of stillbirth following SARS-CoV-2 infection after 22 completed gestational weeks using Cox regression for each country, and combined the results using a random-effects meta-analysis.
SARS-CoV-2 infection after 22 completed gestational weeks was associated with an increased risk of stillbirth (adjusted HR 2.40; 95% CI 1.22 to 4.71). The risk was highest during the first weeks following infection, with an adjusted HR of 5.48 (95% CI 3.11 to 9.63) during the first 2 weeks, 4.38 (95% CI 2.41 to 7.98) during the first 4 weeks, and 3.71 (95% CI 1.81 to 7.59) during the first 6 weeks. Furthermore, the risk was greatest among women infected during the Delta-dominated period (adjusted HR 8.23; 95% CI 3.65 to 18.59), and more modest among women infected during the Index (adjusted HR 3.66; 95% CI 1.89 to 7.06) and Alpha (adjusted HR 2.73; 95% CI 1.13 to 6.59) dominated periods.
We found an increased risk of stillbirth among women who were infected with SARS-CoV-2 after 22 gestational weeks, with the greatest risk during the Delta-dominated period.
一些研究表明,孕期感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的女性死产风险可能会增加。我们的目的是根据孕期感染SARS-CoV-2的情况,并考虑病毒变体,来调查死产风险。
我们利用瑞典、丹麦和挪威的出生登记系统进行了一项基于登记的研究。在2020年5月1日至随访结束期间(瑞典和挪威为2022年1月27日;丹麦为2021年12月31日),共有389949例孕22周及以上的分娩(1013例死产)。我们使用Cox回归对每个国家估算了孕22周及以上感染SARS-CoV-2后的死产风险,并采用随机效应荟萃分析合并结果。
孕22周及以上感染SARS-CoV-2与死产风险增加相关(校正风险比2.40;95%置信区间1.22至4.71)。感染后的最初几周风险最高,感染后前2周校正风险比为5.48(95%置信区间3.11至9.63),前4周为4.38(95%置信区间2.41至7.98),前6周为3.71(95%置信区间1.81至7.59)。此外,在以德尔塔毒株为主的时期感染的女性中风险最大(校正风险比8.23;95%置信区间3.65至18.59),在以原始毒株和阿尔法毒株为主的时期感染的女性中风险相对较小(原始毒株时期校正风险比3.66;95%置信区间1.89至7.06;阿尔法毒株时期校正风险比2.73;95%置信区间1.13至及6.59)。
我们发现孕22周后感染SARS-CoV-2的女性死产风险增加,在以德尔塔毒株为主的时期风险最大。